Legrex

Ticagrelor, the active ingredient in Legrex, is a P2Y12 receptor antagonist presented as an oral tablet for oral use. It is indicated for the management of acute coronary syndrome, myocardial infarction and post‑percutaneous coronary intervention in adult patients. GNH USA supplies Legrex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Legrex is a P2Y12 receptor antagonist used in the antiplatelet therapy pathway for cardiovascular disease. Acute coronary syndrome: reduces the risk of cardiovascular death, myocardial infarction and stroke. Myocardial infarction: prevents recurrent ischemic events after an acute heart attack. Post‑percutaneous coronary intervention: lowers the incidence of stent thrombosis and related complications.

Legrex may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dyspnea: shortness of breath, often transient. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Diarrhea: loose stools, usually self‑limiting. - Increased uric acid: may raise serum levels. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Severe bleeding: life‑threatening hemorrhage, including intracranial bleeding. - Allergic reactions: rash, pruritus, or anaphylaxis. - Thrombocytopenia: marked reduction in platelet count. - Hepatotoxicity: elevated liver enzymes indicating liver injury.

Before initiating Legrex, clinicians should evaluate patient‑specific risk factors and monitor for potential complications. - Assess bleeding risk: review history of hemorrhage or coagulopathy. - Monitor liver function: check baseline enzymes and repeat as indicated. - Adjust for renal impairment: consider dose modification in severe renal dysfunction. - Avoid in active pathological bleeding: discontinue if uncontrolled bleeding occurs. - Use caution in elderly patients: increased susceptibility to bleeding. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Legrex can interact with several drug classes, influencing its antiplatelet efficacy or bleeding risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ticagrelor plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Concurrent use of anticoagulants (e.g., warfarin, heparin): markedly raises bleeding risk.

Moderate Interactions (Monitor Closely): - Aspirin or other NSAIDs: additive effect on bleeding. - Other antiplatelet agents (e.g., clopidogrel): may enhance antithrombotic activity. - Statins metabolized by CYP3A4 (e.g., simvastatin): may increase exposure; dose adjustment may be needed.